MPC2 Overexpression Drives Mitochondrial Oxidative Phosphorylation and Promotes Progression in Diffuse Large B-Cell Lymphoma

• DOI: 10.1007/s10528-025-11100-8
• Publication Date: 2025-04-27T09:12:14Z
• Authors: Haoneng Wu; Qiuran Zhao; Xiaobo Ma; Ying Zhao; Qing Wang; Jinguang Bai; Songling Huang

Abstract Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma with heterogeneous molecular characteristics. Altered metabolism, particularly mitochondrial function, has emerged as a critical factor in cancer progression. However, the role metabolism DLBCL remains poorly understood. This study aimed to identify key factors associated We analyzed transcriptomic data from multiple datasets (GSE83632, TCGA–GTEX, GSE181063, GSE4475) using differential expression analysis, weighted gene co-expression network analysis (WGCNA), and Gene Set Enrichment Analysis (GSEA). The function identified factor, Mitochondrial Pyruvate Carrier 2 (MPC2), were validated clinical samples, cell lines, vivo mouse model xenograft. Integrative bioinformatics MPC2 significantly upregulated DLBCL, enrichment oxidative phosphorylation (OXPHOS) cycle-related genes. overexpression was confirmed samples lines at both mRNA protein levels. Knockdown cells impaired OXPHOS, increased glycolysis, suppressed proliferation, invasion, 3D spheroid formation. In vivo, silencing reduced tumor growth xenograft model. Our findings reveal regulator promoting progression through enhanced OXPHOS. provides new insights into metabolic reprogramming suggests potential therapeutic target for this lymphoma. Graphical